Waldenström Macroglobulinemia and Treatment Advancements With the Use of BTK Inhibitors

Program Description

Waldenström macroglobulinemia (WM) is a rare malignancy accounting for just 2% of all hematological cancers. Patients typically have a long disease course, with median time to symptomatic disease of 5-10 years post diagnosis. There is currently no curative treatment, so goals of therapy are controlling symptoms and managing complications. The mainstay of WM has been systemic chemotherapy, mainly alkylating agents; however, the use of BTK inhibitors, proteasome inhibitors, and anti-CD20 monoclonal antibodies are now foundational to the treatment paradigm. Pharmacists involved in oncology care coordination of patients with WM must be well versed in guideline-recommended use of each of these therapies.

Type of Activity: Knowledge

Release date: December 13, 2021

Expiration date: June 13, 2022

Time to complete activity: 0.5 hour

Fee: Free


Educational Objectives

At the completion of this activity, participants will be able to:

• Outline the pathophysiology of Waldenström macroglobulinemia (WM) and its connection to use of new and emerging drug therapies
• Review clinical guidelines and treatment selection in patients with WM

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hour (0.05 CEU) under the ACPE universal activity number 0290-0000-21-441-H01-P. The activity is available for CE credit through June 13, 2022.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, read the article in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Victoria Nachar, PharmD, BCOP

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Amy Seung PharmD, BCOP, FHOPA; Kylie Ferrentino; Susan Pordon; Brianna Winters; and Chloe Taccetta

An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms